These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 21180379)

  • 1. Tocilizumab: intestinal perforations.
    Prescrire Int; 2010 Oct; 19(109):216. PubMed ID: 21180379
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug eruption induced by IL-6 receptor inhibitor tocilizumab.
    Yoshiki R; Nakamura M; Tokura Y
    J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):495-6. PubMed ID: 19754658
    [No Abstract]   [Full Text] [Related]  

  • 3. Immediate reduction of white blood cell count after tocilizumab administration was observed in some cases.
    Nagamine R; Chen W; Hara T; Kondo K; Sugioka Y
    Mod Rheumatol; 2009; 19(3):348-50. PubMed ID: 19288171
    [No Abstract]   [Full Text] [Related]  

  • 4. Multiple upper gastrointestinal perforations in a 15-year-old patient treated with tocilizumab.
    Pfeil J; Grulich-Henn J; Wenning D; Breil T; Günther P; Lutz T
    Rheumatology (Oxford); 2014 Sep; 53(9):1713-4. PubMed ID: 24625503
    [No Abstract]   [Full Text] [Related]  

  • 5. What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?
    Han ES; Monk BJ
    Gynecol Oncol; 2007 Apr; 105(1):3-6. PubMed ID: 17383545
    [No Abstract]   [Full Text] [Related]  

  • 6. Effectiveness and safety of tocilizumab, an anti-interleukin-6 receptor monoclonal antibody, in a patient with refractory GI graft-versus-host disease.
    Gergis U; Arnason J; Yantiss R; Shore T; Wissa U; Feldman E; Woodworth T
    J Clin Oncol; 2010 Oct; 28(30):e602-4. PubMed ID: 20713858
    [No Abstract]   [Full Text] [Related]  

  • 7. Tocilizumab for rheumatoid and juvenile idiopathic arthritis.
    Bongartz T
    Lancet; 2008 Mar; 371(9617):961-3. PubMed ID: 18358909
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of a patient with remitting seronegative, symmetrical synovitis with pitting oedema with a humanized anti-interleukin-6 receptor antibody, tocilizumab.
    Tanaka T; Hagihara K; Shima Y; Narazaki M; Ogata A; Kawase I; Kishimoto T
    Rheumatology (Oxford); 2010 Apr; 49(4):824-6. PubMed ID: 20008092
    [No Abstract]   [Full Text] [Related]  

  • 9. Interlukin-6 receptor inhibitor tocilizumab: a new treatment option in rheumatoid arthritis?
    Johnson J; Wang MY
    Neurosurgery; 2008 Aug; 63(2):N8. PubMed ID: 18797345
    [No Abstract]   [Full Text] [Related]  

  • 10. Gastrointestinal perforation in metastatic carcinoma: a complication of bevacizumab therapy.
    Collins D; Ridgway PF; Winter DC; Fennelly D; Evoy D
    Eur J Surg Oncol; 2009 Apr; 35(4):444-6. PubMed ID: 18417314
    [No Abstract]   [Full Text] [Related]  

  • 11. Tocilizumab for the treatment of rheumatoid arthritis.
    Tanaka T; Ogata A; Narazaki M
    Expert Rev Clin Immunol; 2010 Nov; 6(6):843-54. PubMed ID: 20979549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is interleukin-6 receptor blockade the Holy Grail for inflammatory diseases?
    Febbraio MA; Rose-John S; Pedersen BK
    Clin Pharmacol Ther; 2010 Apr; 87(4):396-8. PubMed ID: 20305672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma.
    Diaz JP; Tew WP; Zivanovic O; Konner J; Sabbatini PJ; dos Santos LA; Abu-Rustum NR; Chi DS; Aghajanian C; Barakat RR
    Gynecol Oncol; 2010 Mar; 116(3):335-9. PubMed ID: 20004956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti tumour necrosis factor as risk factor for free perforations in Crohn's disease? A case-control study.
    Eshuis EJ; Griffioen GH; Stokkers PC; Ubbink DT; Bemelman WA
    Colorectal Dis; 2012 May; 14(5):578-84. PubMed ID: 21848898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful treatment of reactive arthritis with a humanized anti-interleukin-6 receptor antibody, tocilizumab.
    Tanaka T; Kuwahara Y; Shima Y; Hirano T; Kawai M; Ogawa M; Arimitsu J; Hagihara K; Narazaki M; Ogata A; Kawase I; Kishimoto T
    Arthritis Rheum; 2009 Dec; 61(12):1762-4. PubMed ID: 19950316
    [No Abstract]   [Full Text] [Related]  

  • 16. [Generation mechanisms and management strategies of adverse reactions to Bevacizumab during cancer treatment].
    Ge FJ; Xu JM
    Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):481-6. PubMed ID: 21029688
    [No Abstract]   [Full Text] [Related]  

  • 17. [Tocilizumab in rheumatoid arthritis. Interleukin 6 as a new target].
    Heinzl S
    Med Monatsschr Pharm; 2008 Dec; 31(12):450-3. PubMed ID: 19133593
    [No Abstract]   [Full Text] [Related]  

  • 18. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.
    Genovese MC; McKay JD; Nasonov EL; Mysler EF; da Silva NA; Alecock E; Woodworth T; Gomez-Reino JJ
    Arthritis Rheum; 2008 Oct; 58(10):2968-80. PubMed ID: 18821691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exacerbation of chronic active Epstein-Barr virus infection in a patient with rheumatoid arthritis receiving humanised anti-interleukin-6 receptor monoclonal antibody.
    Ogawa J; Harigai M; Akashi T; Nagasaka K; Suzuki F; Tominaga S; Miyasaka N
    Ann Rheum Dis; 2006 Dec; 65(12):1667-9. PubMed ID: 17105857
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical value of blocking IL-6 receptor.
    Mima T; Nishimoto N
    Curr Opin Rheumatol; 2009 May; 21(3):224-30. PubMed ID: 19365268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.